CEO Aminov Buys 83,500 RSUs at Zero Cash Cost, Betting on Mira Pharmaceuticals’ Next Clinical Milestone
CEO Aminov’s March 30 RSU purchase shows strong belief in Mira’s Phase‑2 prospects, potentially boosting stock after a 52‑week low.
3 minutes to read